Resources
FDA Approved Drugs
Vanflyta (Quizartinib dihydrochloride)
Treatment For: Acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive
Manufactured By: Daiichi Sankyo
Date Of Approval: 2023-07-20
Ycanth (Cantharidin)
Treatment For: Molluscum contagiosum in adult and pediatric patients 2 years of age and older
Manufactured By: Verrica Pharmaceuticals
Date Of Approval: 2023-07-21
Xdemvy (Lotilaner)
Treatment For: Demodex blepharitis
Manufactured By: Tarsus Pharmaceuticals
Date Of Approval: 2023-07-25
Zurzuvae (Zuranolone)
Treatment For: Postpartum depression (PPD) in Adults
Manufactured By: Sage Therapeutics
Date Of Approval: 2023-08-04
Izervay (Avacincaptad pegol sodium)
Treatment For: Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Manufactured By: Iveric bio
Date Of Approval: 2023-08-14
Talvey (Talquetamab)
Treatment For: Relapsed or refractory multiple myeloma
Manufactured By: Janssen Biotech
Date Of Approval: 2023-08-09
Elrexfio (Elranatamab)
Treatment For: Relapsed or refractory Multiple Myeloma
Manufactured By: Pfizer Inc.
Date Of Approval: 2023-08-14
Sohonos (Palovarotene)
Treatment For: Reduction in the volume of new heterotopic ossification
Manufactured By: Ipsen Biopharmaceuticals
Date Of Approval: 2023-08-16
Veopoz (Pozelimab)
Treatment For: CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease
Manufactured By: Regeneron Pharmaceuticals
Date Of Approval: 2023-08-18
Aphexda (Motixafortide acetate)
Treatment For: Mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
Manufactured By: BioLineRx
Date Of Approval: 2023-10-08
Ojjaara (Momelotinib dihydrochloride monohydrate)
Treatment For: Intermediate or high-risk myelofibrosis (MF)
Manufactured By: GlaxoSmithKline
Date Of Approval: 2023-10-15
Exxua (Gepirone hydrochloride)
Treatment For: Major depressive disorder
Manufactured By: Fabre-Kramer Pharmaceuticals
Date Of Approval: 2023-10-22
Pombiliti (Cipaglucosidase alfa)
Treatment For: Late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)
Manufactured By: Amicus Therapeutics
Date Of Approval: 2023-10-28
Rivfloza (Nedosiran sodium)
Treatment For: Moderately to severely active ulcerative colitis in adults
Manufactured By: Novo Nordisk
Date Of Approval: 2023-10-29
Velsipity (Etrasimod arginine)
Treatment For: Active Ulcerative Colitis (UC) in Adults
Manufactured By: Pfizer Inc
Date Of Approval: 2023-10-12
Zilbrysq (Zilucoplan sodium)
Treatment For: Generalized myasthenia gravis (gMG)
Manufactured By: UCB Inc
Date Of Approval: 2023-10-17
Bimzelx (Bimekizumab)
Treatment For: Treatment of moderate to severe plaque psoriasis
Manufactured By: UCB Inc
Date Of Approval: 2023-10-17
Agamree (Vamorolone)
Treatment For: Moderately to severely active ulcerative colitis in adults
Manufactured By: Santhera Pharmaceuticals
Date Of Approval: 2023-10-26
Omvoh (Mirikizumab)
Treatment For: Moderately to severely active ulcerative colitis in adults
Manufactured By: Eli Lilly
Date Of Approval: 2023-10-26
Loqtorzi (Toripalimab)
Treatment For: Metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) and h recurrent unresectable
Manufactured By: Coherus BioSciences
Date Of Approval: 2023-10-27
Fruzaqla (Fruquintinib)
Treatment For: Adult patients with Metastatic Colorectal Cancer (mCRC)
Manufactured By: Takeda Pharmaceuticals
Date Of Approval: 2023-11-08
Defencath (Taurolidine and Heparin)
Treatment For: Reduce the incidence of catheter-related bloodstream infections
Manufactured By: CorMedix Inc
Date Of Approval: 2023-11-15
Augtyro (Repotrectinib)
Treatment For: Locally advanced or metastatic NSCLC
Manufactured By: Bristol-Myers Squibb
Date Of Approval: 2023-11-15
Ryzneuta (Efbemalenograstim alfa)
Treatment For: Non-myeloid Malignancies- Decrease the incidence of infection
Manufactured By: Evive Biotechnology
Date Of Approval: 2023-11-16
Truqap (Capivasertib)
Treatment For: Metastatic Breast Cancer
Manufactured By: AstraZeneca
Date Of Approval: 2023-11-16
View All
FDA Approved Drugs 2023 (Country Specific Regulations
Country-specific regulations that allow the import of unapproved medicine
Select Country
Importing a medicine that is unapproved by the Therapeutic Goods Administration (TGA) is possible under the Personal Importation Scheme.
We are here to support you.
Contact us to find out how our services can help achieve your goals.
A member of our team will contact you shortly.